Boston Scientific: Eluvia Drug-Eluting Stent System Exhibits Superiority to Bare Metal Stents
06 Outubro 2021 - 4:13PM
Dow Jones News
By Michael Dabaie
Boston Scientific Corp. said its Eluvia Drug-Eluting Vascular
Stent System exhibited superiority compared to bare metal
stents.
Data presented at the Vascular InterVentional Advances meeting
in Las Vegas included one-year results from the Eminent trial. The
data demonstrated superiority of the Eluvia stent compared to
self-expanding bare metal stents for peripheral artery disease and
superficial femoral artery or popliteal artery lesions up to 210
millimeters in length.
The study enrolled 775 patients.
Shares were up 0.3%, to $42.57, in afternoon trading after being
lower earlier in the session.
Boston Scientific said before the market open Wednesday it
agreed to acquire Baylis Medical Company Inc. for an upfront
payment of $1.75 billion.
--Colin Kellaher contributed to this article
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 06, 2021 14:58 ET (18:58 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Boston Scientific (NYSE:BSX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Boston Scientific (NYSE:BSX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
